Stock events for Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics' stock price has experienced significant fluctuations due to regulatory and clinical trial developments. The FDA issued a Complete Response Letter (CRL) for Deramiocel's BLA, leading to a stock price drop. The stock saw a surge when Capricor announced positive topline results from its Phase 3 HOPE-3 trial for Deramiocel. The FDA requested the full HOPE-3 clinical study report to address the CRL. CAPR's share price increased by 88.61% between March 4, 2025, and March 3, 2026.
Demand Seasonality affecting Capricor Therapeutics, Inc.’s stock price
Capricor Therapeutics, Inc. does not currently have commercialized products with traditional demand seasonality. The company's revenue is primarily derived from collaborations and grants. Analyses of Capricor's stock price have shown recurring patterns over a calendar year, indicating stock price seasonality rather than product demand seasonality.
Overview of Capricor Therapeutics, Inc.’s business
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, primarily Duchenne muscular dystrophy (DMD). Its lead product candidate is Deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy in Phase 3 clinical development for DMD, designed to address both cardiac and skeletal muscle function. Capricor is also developing its StealthX™ exosome technology platform for various applications. The company generates revenue primarily through collaboration payments and grants.
CAPR’s Geographic footprint
Capricor Therapeutics, Inc. is headquartered in San Diego, California, United States. The company has a strategic distribution and commercialization agreement with Nippon Shinyaku Co., Ltd. for Deramiocel in the U.S. and Japan, subject to regulatory approval. The United States is a geographical segment for the company.
CAPR Corporate Image Assessment
Capricor Therapeutics' brand reputation has been influenced by the progress and setbacks in its clinical development, particularly concerning Deramiocel for DMD. The FDA's Complete Response Letter (CRL) negatively impacted the company's reputation and led to a class-action lawsuit. Positive Phase 3 HOPE-3 trial results have likely had a positive impact on the company's reputation. Subsequent regulatory updates suggest continued engagement with regulatory bodies and a potential path towards approval.
Ownership
Approximately 59.98% of Capricor Therapeutics' stock is held by institutional shareholders, including BlackRock, Inc., Vanguard Group Inc, and Point72 Asset Management, L.P.. Nippon Shinyaku Co Ltd is also a significant shareholder, owning 15.51% of the company and is considered an insider.
